FDA review: Long-acting asthma drugs pose serious risks
The FDA should revoke clearance for asthma drugs known as long-acting beta agonists for children in light of clinical evidence linking them to a higher risk of asthma attacks and death, according to a review from the agency's drug-safety personnel. The FDA plans to gather a panel of outside experts this week to evaluate the safety of AstraZeneca's Symbicort, Novartis AG's Foradil and GlaxoSmithKline's Advair and Serevent.
Reuters | 12/05
This story published in BIO SmartBrief on 12/08/2008
More from SmartBrief:
FDA: Most drugmakers meeting timelines of postmarketing studies
Wednesday, September 9, 2009
Pozen receives $10M for Vimovo's regulatory milestone
Tuesday, September 1, 2009
Merck KGaA seeks FDA approval of MS drug cladribine
Thursday, October 1, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|